ArticleThe oncologist2019

First-in-Human Phase I Study of MBC-11, a Novel Bone-Targeted Cytarabine-Etidronate Conjugate in Patients with Cancer-Induced Bone Disease.

Shawn Patrick Zinnen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.